Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.3652W HIGH $15.67
Volume
1.94 M
Value Traded
23.81 M
Short % Float
3.14%
Days to Cover
8.5
+4.22%Week
+10.47%1 Month
+17.82%3 Month
-1.5%6 Month
-6.17%5 Year
+1,243.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.53 B
EPS (TTM)
0.59
P/E Ratio
23.51
Ent. Value
11.32 B
Total Shares
834.67 M
Float Shares
833.03 M
Insiders
0.00%
Institutions
14.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RDY Catalyst Timeline
Dated clinical, regulatory and corporate events for Dr. Reddy's Laboratories Ltd
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dr. Reddy's Laboratories Ltd
647Total events
3Upcoming
191Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1EU Approval
Subscribe to view catalyst details
Event history 50
▲FDA ApprovalZytorviApprovedFDA Decision
DCGI approves Zytorvi (toripalimab) with cisplatin and paclitaxel for first-line ESCC in India
unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)source ↗
▲Product LaunchPost-Market
First-to-market launch of Bosutinib Tablets 400mg in the United States
Oncology (Tyrosine Kinase Inhibitor)source ↗
◆Management ChangeCorporate
Mr. Sushrut Kulkarni resigns as Global Head of IPDO and Senior Management Personnel
◆FDA Filing AcceptedSemaglutideApprovedRegulatory Filing
Response submitted to Health Canada for Semaglutide; goal date set 6 months from response
diabetes/obesitysource ↗
▲FDA ApprovalFDA Decision
Health Canada approval (Notice of Compliance) for generic Semaglutide Injection
type 2 diabetessource ↗
▲FDA ApprovalObedaApprovedFDA Decision
DCGI approval for generic semaglutide (Obeda)
Type 2 Diabetessource ↗
▲Product LaunchObedaApprovedPost-Market
Launch of Obeda (semaglutide injection) in India
Type 2 Diabetessource ↗
▲Full ResultsObedaApprovedClinical Data
Phase III study results for Obeda showing non-inferior efficacy and comparable safety
Type 2 Diabetessource ↗
▼Trial Stopped FutilityTrial
IDMC recommends discontinuation of TACTI-004 Phase III trial for efti in firstline NSCLC due to futility
firstline non-small cell lung cancersource ↗
▲IP Litigation RulingSemaglutideApprovedIP / Competition
Delhi High Court Division Bench upholds order allowing Dr. Reddy's to manufacture and export Semaglutide where Novo Nordisk has no patent
▲FDA Feedback ReceivedFDA Meeting
SEC concluded investigation, no enforcement action recommended
▲Partnership / LicenseProgynovaCorporate
Dr. Reddy's acquires Progynova trademark and related assets for India from Mercury Pharma Group
estrogen deficiency symptoms, postmenopausal osteoporosissource ↗
▲Partnership / LicenseCyclo-ProgynovaCorporate
Dr. Reddy's acquires Cyclo-Progynova trademark and related assets for India from Mercury Pharma Group
estrogen deficiency symptomssource ↗
▲Patent ExpiryIP / Competition
License to sell generic lenalidomide without volume limitation begins
▲Product LaunchPost-Market
License to sell generic lenalidomide capsules in U.S. without volume limitation beginning on January 31, 2026
▲Product LaunchPost-Market
First-to-market launch of generic Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the U.S.
temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dandersource ↗
▲Product LaunchPost-Market
First-to-market launch of OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S.
temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dandersource ↗
◆Product LaunchSemaglutideApprovedPost-Market
Expected launch of Semaglutide in Canada in Q4FY26 or Q1FY27
diabetes/obesitysource ↗
▲Full ResultsToripalimabApprovedClinical Data
Final OS analysis of JUPITER-06 published in Annals of Oncology
advanced esophageal squamous cell carcinoma (ESCC)source ↗
▼Form 483 IssuedCMC / Inspection
Form 483 issued with 5 observations at FTO-SEZ PU01 facility
◆Pre Approval InspectionCMC / Inspection
Pre-Approval Inspection (PAI) at FTO-SEZ PU01 facility
▲Topline ReadoutAUR112Clinical Data
Initial data from Phase 1 study of AUR112 shows 63.6% ORR in efficacy-evaluable population
relapsed/refractory lymphoid malignanciessource ↗
▲EU ApprovalAVT03ApprovedEx-US Regulatory
European Commission grants marketing authorization for AVT03 (denosumab) biosimilar
osteoporosis; prevention of bone complications in advanced cancer; giant cell tumour of bonesource ↗
▲Form 483 IssuedCMC / Inspection
USFDA GMP inspection at API facility (CTO-SEZ) concluded with zero observations
●Quarterly UpdateCorporate
Unaudited financial results for quarter and half-year ended September 30, 2025
▲AcquiredSTUGERONCorporate
Acquisition of Stugeron and related brands across 18 markets in APAC and EMEA from Janssen Pharmaceutica
anti-vertigosource ↗
▲Product LaunchTegoprazanPost-Market
Launch of Tegoprazan under brand name PCAB in India
gastrointestinalsource ↗
▲Product LaunchLinaclotidePost-Market
Launch of Linaclotide under brand name Colozo in India
gastrointestinalsource ↗
▲Partnership / LicenseLenacapavirCorporate
Partnership with Unitaid, Clinton Health Access Initiative, and Wits RHI to make Lenacapavir accessible in low- and middle-income countries
HIV preventionsource ↗
▲CHMP Positive OpinionDenosumabFiledEx-US Regulatory
Positive CHMP opinion for denosumab biosimilar candidate
▼Complete Response LetterRituxanApprovedFDA Decision
USFDA issued Complete Response Letter for Rituximab biosimilar BLA due to unresolved observations
▼Form 483 IssuedCMC / Inspection
USFDA issued Form 483 with seven observations after GMP inspection at Mirfield API facility
▲Manufacturing MilestoneCMC / Inspection
USFDA closed GMP and Pre-Approval Inspection at FTO 11 with VAI outcome; EIR received
▲FDA ApprovalSemaglutideApprovedFDA Decision
SEC under CDSCO recommended approval for Semaglutide injection in India
▲Form 483 IssuedCMC / Inspection
USFDA inspection at FTO 11 facility classified as VAI, EIR received
Past FDA Catalysts and PDUFA Decisions
How RDY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-31 | Zimrixby (rituximab-cdxx) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 23%
Mid Cap(rank 152 of 657)
Percentile Rank
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from INR to USD, to Mar 2026; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Central Nervous System | |||
| Pain Management | |||
| Diabetology | |||
| Antiinfective | |||
| Nutraceutical | |||
| Anti-Infective | |||
| Genitourinary |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUR103 Calcium Small moleculeNCT07640737 | Neuroendocrine (NE) Tumors | Phase 2 | NOT YET_RECRUITING | 30 | Jan 31, 2029 | ||||||
| AUR107 Small moleculeNCT05865002 | Relapsed Malignant Solid Neoplasm | Phase 1 | RECRUITING | 50 | Jun 1, 2027 | ||||||
| DRL_AB Monoclonal antibodyNCT07744828 | Undisclosed | Phase 1 | NOT YET_RECRUITING | 160 | Dec 29, 2026 | ||||||
| AUR108 Small moleculeNCT05984147 | Relapsed Advanced Lymphomas | Phase 1 | RECRUITING | 40 | Aug 30, 2027 | ||||||
| AUR112 Small moleculeNCT06755450 | Relapsed Advanced Lymphomas | Phase 1 | RECRUITING | 40 | Jan 15, 2028 | ||||||
| AUR101 Small moleculeCompletedNCT04855721 | Plaque Psoriasis | Phase 2 | COMPLETED | 141 | Dec 10, 2022 | ||||||
| DRL_RI Monoclonal antibodyCompletedNCT02296775 | Rheumatoid Arthritis | Phase 3 | COMPLETED | 416 | Oct 5, 2017 | ||||||
| DRL_RI Monoclonal antibodyCompletedNCT03976102 | Follicular Lymphoma | Phase 3 | COMPLETED | 317 | Feb 27, 2023 | ||||||
| Abametapir 0.74% w/w Small moleculeMarketedNCT02097485 | Head Lice Infestation | Phase 3 | COMPLETED | 754 | Oct 1, 2014 | ||||||
| DFN-11 Small moleculeMarketedNCT02569853 | Episodic Migraine | Phase 3 | COMPLETED | 268 | Feb 26, 2018 | ||||||
| Ha44 Small moleculeMarketedNCT01907490 | Head Lice Infestation | Phase 2 | COMPLETED | 38 | Dec 1, 2013 | ||||||
| DFN-11 Small moleculeMarketedNCT02571049 | Rapidly Escalating Migraine | Phase 2 | COMPLETED | 24 | May 1, 2016 | ||||||
| Amlodipine/Atorvastatin calcium Small moleculeMarketedNCT01505998 | Fed | Phase 1 | COMPLETED | 49 | May 1, 2007 | ||||||
| Ha44 Small moleculeMarketedNCT01518699 | Pediculosis | Phase 1 | COMPLETED | 57 | May 1, 2012 | ||||||
| Abametapir 0.74% w/w Small moleculeMarketedNCT02061813 | Head Lice | Phase 1 | COMPLETED | 278 | May 1, 2014 | ||||||
| Amlodipine/Atorvastatin calcium Small moleculeMarketedNCT01506011 | Fasting | Phase 1 | COMPLETED | 50 | Apr 1, 2007 | ||||||
| Sumatriptan Small moleculeMarketedNCT01269281 | Undisclosed | Phase 1 | COMPLETED | 50 | Jul 1, 2005 |
Clinical Trial Results
Readouts, endpoints and source filings for every RDY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AUR112 | relapsed/refractory lymphoid malignancies | Phase 1 | 2025-12-02 | overall response rate: 63.6%; efficacy evaluable population: 63.6%; intent to treat group: 58.3%; patients evaluable for safety: 13; patients evaluable for efficacy: 11Read More | Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid MalignanciesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RDY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RDY for Q2 2026. | ||||
RDY Institutional Ownership Trends
RDY Short Interest
Shares sold short, counted twice a month.
3.14%
Short % of Float
of tradable shares sold short
26.1M
Shares Sold Short
-7.9% vs prior count
8.5 High
Days to Cover
trading days of normal volume to buy every short share back
3.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RDY ranks across every disease it competes in
Competitive Position is a premium feature
See how RDY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRDY News
RDYZytorvi® receives DCGI approval for second indication in India
Dr. Reddy's Laboratories announced DCGI approval for Zytorvi® (toripalimab) in India, enabling its use with cisplatin and paclitaxel for first-line treatment of advanced esophageal squamous cell carcinoma. The approval follows positive results from the Phase 3 JUPITER-06 trial, showing a 42% reduction in disease or death risk. This marks a significant expansion of immunotherapy options in India.
Read more →RDYAnnouncement of an exclusive agreement with Takeda to promote and distribute QDENGA®
Dr. Reddy's Laboratories has entered an exclusive agreement with Takeda to promote and distribute the dengue vaccine QDENGA in India's private market. The vaccine, approved by India's CDSCO for individuals aged 4-60, is expected to be available in early 2027. This collaboration aims to address the growing dengue burden in India and improve access to vaccination.
Read more →RDYExpanding our collaboration on LENACAPAVIR
Dr. Reddy's Laboratories has expanded its collaboration with Gilead Sciences through a royalty-free licensing agreement for once-yearly lenacapavir, aimed at HIV prevention. This agreement builds on a previous arrangement for twice-yearly lenacapavir and focuses on improving access in low- and lower-middle-income countries. The investigational drug is currently under evaluation in a Phase 3 study.
Read more →RDYAnnouncing the launch of Nivorz® (Nivolumab Biosimilar) in India
Dr. Reddy's Laboratories has launched NIVORZ® (Nivolumab Biosimilar) in India, marking a significant entry into the biosimilar immuno-oncology market. Developed in-house, NIVORZ® aims to enhance patient access to high-quality nivolumab therapy at an affordable price. The product has received approval from the Drugs Controller General of India following a multi-country clinical development program.
Read more →RDYUS FDA approval for Rituximab biosimilar
Dr. Reddy's Laboratories has received FDA approval for its rituximab biosimilar, enhancing its biosimilars portfolio in the U.S. The approval follows a successful Pre-License Inspection at its manufacturing facility in India. The biosimilar has already been commercialized in several international markets and is supported by comprehensive evidence demonstrating its similarity to the reference product.
Read more →RDYDr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy's Laboratories Limited has filed its Annual Report on Form 20-F. This report is a standard requirement for foreign companies listed in the U.S. and provides detailed financial information and disclosures. The filing reflects the company's commitment to transparency and compliance with regulatory standards.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.c
Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, on June 13, 2026. This product launch marks an expansion of Dr. Reddy’s oncology portfolio, made possible through collaboration with MSN Laboratories. The launch positions Dr. Reddy's for a significant role in the oncology market, as Bosulif recorded approximately $253.8 million in U.S. sales within the latest 12-month period. The exclusive marketing rights held by Dr. Reddy's are expected to enhance patient access to affordable and high-quality cancer treatment.
Read more →RDYSub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings
Dr. Reddy's Laboratories announced that its management will participate in an investor conference scheduled for June 16-17, 2026, organized by Investec in London. The meetings will be conducted in person with institutional investor groups. The schedule is noted to be subject to change due to any unforeseen circumstances affecting either the investors or the company. This disclosure complies with the SEBI's regulations for investor meetings.
Read more →RDYSub: Allotment of Equity Shares on exercise of Stock Options under ESOPs
Dr. Reddy's Laboratories has announced the allotment of 12,100 equity shares to eligible employees as part of its Employee Stock Options Scheme. This issuance follows the exercise of stock options under the Dr. Reddy's Employees Stock Option Scheme, 2002 and the ADR Stock Option Scheme, 2007. The shares have a par value of Re. 1 each and were allotted on June 5, 2026. This move reflects the company's commitment to employee participation and follows the regulatory guidelines stipulated by SEBI.
Read more →RDYDr. Reddy's Laboratories Ltd . 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.
Dr. Reddy's Laboratories Ltd has announced its participation in an investor conference organized by Bank of America in Hyderabad on June 5, 2026. The meeting will be conducted in person and is scheduled for 08:00 to 09:00 IST. The company emphasized that the schedule is subject to change based on unforeseen circumstances. This engagement reflects the company's commitment to maintaining strong investor relations.
Read more →RDYDr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories Ltd. has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, making it the first company to obtain market authorization in Canada. This approval allows Dr. Reddy's to commence the commercialization, sale, and distribution of the medication, which aims to improve glycemic control in patients with type 2 diabetes. Dr. Reddy's is well-positioned to provide this important treatment option to Canadian patients, bolstered by its in-house development capabilities. With a substantial number of Canadians suffering from diabetes, this approval also strengthens the company's diabetes management portfolio in a key market.
Read more →RDYDr. Reddy's to release Q4 and full year FY26 results on Tuesday, May 12th, 2026; Earnings call slated @19:30 PM IST / 10:00 AM ET
Dr. Reddy's Laboratories Ltd. has announced that it will release its financial results for the fourth quarter and full year fiscal 2026 on May 12, 2026. The company's management will host an earnings call at 19:30 PM IST / 10:00 AM ET to discuss its financial performance. This notification is part of the company's commitment to keeping investors informed about its operations. Details will be available on the company's website and via stock exchanges.
Read more →RDYNational Stock Exchange of India Ltd.
Dr. Reddy's Laboratories Limited announced that the Board of Directors will consider the proposal for recommending the final dividend for the fiscal year 2025-26. This follows an earlier communication made on March 23, 2026. The decision regarding the dividend will be deliberated in an upcoming board meeting. No specific details about the dividend amount or other financial aspects were disclosed in the announcement.
Read more →About Dr. Reddy's Laboratories Ltd
BIOPHARMAWATCH ELITE PLUS
Trade the next RDY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime